SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-042298
Filing Date
2024-05-13
Accepted
2024-05-13 16:06:00
Documents
78
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0205291-10q_unicycive.htm   iXBRL 10-Q 769378
2 CERTIFICATION ea020529101ex31-1_unicycive.htm EX-31.1 11495
3 CERTIFICATION ea020529101ex31-2_unicycive.htm EX-31.2 11508
4 CERTIFICATION ea020529101ex32-1_unicycive.htm EX-32.1 3705
5 CERTIFICATION ea020529101ex32-2_unicycive.htm EX-32.2 3666
  Complete submission text file 0001213900-24-042298.txt   6004963

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE uncy-20240331.xsd EX-101.SCH 64605
7 XBRL CALCULATION FILE uncy-20240331_cal.xml EX-101.CAL 35355
8 XBRL DEFINITION FILE uncy-20240331_def.xml EX-101.DEF 322838
9 XBRL LABEL FILE uncy-20240331_lab.xml EX-101.LAB 565923
10 XBRL PRESENTATION FILE uncy-20240331_pre.xml EX-101.PRE 323526
82 EXTRACTED XBRL INSTANCE DOCUMENT ea0205291-10q_unicycive_htm.xml XML 666578
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40582 | Film No.: 24939011
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)